Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1973 Oct;36(5):747–752. doi: 10.1136/jnnp.36.5.747

Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease

William J Weiner 1, Harold L Klawans Jr 1
PMCID: PMC494452  PMID: 4753871

Abstract

Lumbar cerebrospinal fluid homovanillic acid levels were estimated in 60 patients with Parkinsonism before and during levodopa treatment. There was a slight negative correlation between pretreatment CSF homovanillic acid levels and disability. There was no correlation between pretreatment homovanillic acid levels and clinical response to levodopa. Patients with high pretreatment levels did as well as those with depressed levels. High (normal or near normal) levels of CSF homovanillic acid in a patient with Parkinsonism do not necessarily indicate that the Parkinsonism will not respond to levodopa. These patients should receive the benefit of a trial of levodopa. There was also no correlation between homovanillic acid level during tratment and improvement. Patients with minimal increases in CSF homovanillic acid responded as well as those with greater elevations. Failure of levodopa to increase CSF homovanillic acid significantly does not indicate that the patient will not respond to levodopa and that levodopa should be discontinued. Other factors, such as vitamin B6 consumption, should be investigated.

Full text

PDF
747

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDEN N. E., ROOS B. E., WERDINIUS B. On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method. Life Sci. 1963 Jul;(7):448–458. doi: 10.1016/0024-3205(63)90132-2. [DOI] [PubMed] [Google Scholar]
  2. Bartholini G., Pletscher A., Tissot R. On the origin of homovanillic acid in the cerebrospinal fluid. Experientia. 1966 Sep 15;22(9):609–610. doi: 10.1007/BF01895283. [DOI] [PubMed] [Google Scholar]
  3. Bowers M. B., Jr Clinical measurements of central dopamine and 5-hydroxytryptamine metabolism: reliability and interpretation of cerebrospinal fluid acid monoamine metabolite measures. Neuropharmacology. 1972 Jan;11(1):101–111. doi: 10.1016/0028-3908(72)90061-5. [DOI] [PubMed] [Google Scholar]
  4. CANTER G. J., DE LA TORRE R., MIER M. A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis. 1961 Aug;133:143–147. doi: 10.1097/00005053-196108000-00010. [DOI] [PubMed] [Google Scholar]
  5. EHRINGER H., HORNYKIEWICZ O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–1239. doi: 10.1007/BF01485901. [DOI] [PubMed] [Google Scholar]
  6. Godwin-Austen R. B. Kantamaneni BD, Curzon G:Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF. J Neurol Neurosurg Psychiatry. 1971 Jun;34(3):219–223. doi: 10.1136/jnnp.34.3.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Guldberg H. C., Ashcroft G. W., Crawford T. B. Concentrations of 5-hydroxyindolylacetic acid and homovanillic acid in the cerebrospinal fluid of the dog before and during treatment with probenecid. Life Sci. 1966 Sep;5(17):1571–1575. doi: 10.1016/0024-3205(66)91026-5. [DOI] [PubMed] [Google Scholar]
  8. Hinterberger H., Andrews C. J. Catecholamine metabolism during oral administration of levodopa. Arch Neurol. 1972 Mar;26(3):245–252. doi: 10.1001/archneur.1972.00490090071005. [DOI] [PubMed] [Google Scholar]
  9. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966 Jun;18(2):925–964. [PubMed] [Google Scholar]
  10. Jequier E., Dufresne J. J. Biochemical investigations in patients with Parkinson's disease treated with L-dopa. Neurology. 1972 Jan;22(1):15–21. doi: 10.1212/wnl.22.1.15. [DOI] [PubMed] [Google Scholar]
  11. Johansson B., Roos B. E. 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. Life Sci. 1967 Jul 1;6(13):1449–1454. doi: 10.1016/0024-3205(67)90193-2. [DOI] [PubMed] [Google Scholar]
  12. Klawans H. L., Jr Cerebrospinal fluid homovanillic acid in Huntington's chorea. J Neurol Sci. 1971 Jul;13(3):277–279. doi: 10.1016/0022-510x(71)90032-3. [DOI] [PubMed] [Google Scholar]
  13. Klawans H. L., Jr Effect of vitamin B 6 on levodopa-induced changes in spinal fluid homovanillic acid. J Neurol Sci. 1971 Dec;14(4):421–426. doi: 10.1016/0022-510x(71)90177-8. [DOI] [PubMed] [Google Scholar]
  14. Klawans H. L., Jr, Garvin J. S. Treatment of parkinsonism with L-dopa (study of 105 patients). Dis Nerv Syst. 1969 Nov;30(11):737–746. [PubMed] [Google Scholar]
  15. Rinne U. K., Sonninen V. Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease. Neurology. 1972 Jan;22(1):62–67. doi: 10.1212/wnl.22.1.62. [DOI] [PubMed] [Google Scholar]
  16. SHARMAN D. F. A fluorimetric method for the estimation of 4-hydroxy-3-methoxyphenylacetic acid (homovanillic acid) and its identification in brain tissue. Br J Pharmacol Chemother. 1963 Feb;20:204–213. doi: 10.1111/j.1476-5381.1963.tb01310.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Weiner W., Harrison W., Klawans H. L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism. Life Sci. 1969 Sep 1;8(17):971–976. doi: 10.1016/0024-3205(69)90428-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES